HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Watt, S. V. Articles by Hayakawa, Y. Search for Related Content PubMed PubMed Citation Articles by Watt, S. V. Articles by Hayakawa, Y.

IFN--Dependent Recruitment of Mature CD27^high NK Cells to Lymph Nodes Primed by Dendritic Cells

Sally V. Watt^*, Daniel M. Andrews^*, Kazuyoshi Takeda^*,, Mark J. Smyth^* and Yoshihiro Hayakawa^1,*

^* Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, Victoria, Australia; and Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan

NK cells have been proposed to be an initial source of IFN- that supports either Th1 or CTL priming. Although NK cells reside in naive lymph nodes (LN) at a very low frequency, they can be recruited into LN draining sites of infection, inflammation, or immunization where they potentially influence adaptive immunity. In this study, we report that mature CD27^high NK cells are predominantly recruited into the draining LN following dendritic cell (DC) challenge. Importantly, the recruitment of the CD27^high NK cell subset in the draining LN was dependent on host IFN- and the activation status of NK cells. Endogenous epidermal DC migration induced by hapten challenge also triggers NK cell recruitment to the draining LN in an IFN--dependent mechanism. Thus, our results identify that CD27^high NK cells are the dominant population recruited to the draining LN and NK cell recruitment requires endogenous IFN- in coordinating with DC migration.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Address correspondence and reprint requests to Dr. Yoshihiro Hayakawa at the current address: Pharmacology Department, Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co. Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan. E-mail address: yoshihiro_hayakawa{at}merck.com

² Abbreviations used in this paper: DC, dendritic cell; LN, lymph node; WT, wild type; MHC II, MHC class II; -GalCer, -galactosylceramide.